JUNEL FE 1.5/30
Clinical safety rating
cautionComprehensive clinical and safety monograph for JUNEL FE 1.5/30 (JUNEL FE 1.5/30).
Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
| Metabolism | Ethinyl estradiol: primarily metabolized via CYP3A4; norethindrone: primarily reduced and conjugated, with CYP3A4 involvement. |
| Excretion | Renal: 30-50% (norethindrone metabolites), 20-40% (ethinyl estradiol metabolites); biliary/fecal: 20-30% (norethindrone), 30-50% (ethinyl estradiol). Conjugated metabolites excreted in bile and undergo enterohepatic recirculation. |
| Half-life | Norethindrone: 6-12 hours (terminal, multidose); ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; missed doses may reduce contraceptive efficacy. |
| Protein binding | Norethindrone: 60-80% bound to albumin and SHBG; ethinyl estradiol: ~98% bound to albumin (specific binding to SHBG not significant). |
| Volume of Distribution | Norethindrone: 2-4 L/kg; ethinyl estradiol: 5-10 L/kg. Clinical meaning: Indicates extensive tissue distribution and slow clearance; Vd may increase in obesity. |
| Bioavailability | Oral: Norethindrone ~60-70% (first-pass metabolism); ethinyl estradiol ~40-50% (presystemic conjugation in gut and liver). |
| Onset of Action | Oral: Onset of contraceptive effect within 7 days of consistent dosing; inhibition of ovulation occurs by day 7 of first cycle if taken on day 1 of menses. |
| Duration of Action | Oral: 24 hours (daily dosing required). Clinical notes: Continuous suppression of gonadotropins requires consistent daily intake; missed doses >24 hours increase failure risk. |
| Molecular Weight | 376.5 |
| Action Class | Oral Contraceptive; Estrogen/Progestin Combination |
One tablet orally once daily, each tablet containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets).
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment provided in labeling; use with caution in patients with renal impairment. GFR-based modifications not established. |
| Liver impairment | Contraindicated in patients with hepatic impairment (Child-Pugh class B or C) or active liver disease. No specific dose adjustment for mild impairment; use with caution. |
| Pediatric use | Not indicated for use before menarche. In post-menarche adolescents, dosing is the same as adults: one tablet daily for 21 days, then 7 days placebo. |
| Geriatric use | Not indicated for use in postmenopausal women; no specific geriatric dosing considerations. |
| 1st trimester | Contraindicated due to risk of birth defects; use only if benefits outweigh risks. |
| 2nd trimester | Contraindicated due to risk of fetal toxicity; avoid use. |
| 3rd trimester | Contraindicated due to risk of fetal harm; avoid use. |
Clinical note
Comprehensive clinical and safety monograph for JUNEL FE 1.5/30 (JUNEL FE 1.5/30).
| Placental transfer | Estrogens and progestins cross the placenta; evidence of fetal risk. |
| Breastfeeding | Contraindicated during breastfeeding; may reduce milk production and pass into breast milk. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | First trimester: Inadvertent use does not increase risk of major birth defects. Second and third trimesters: Avoid use due to risk of fetal harm from estrogenic and progestogenic effects, including potential genitourinary tract abnormalities. Postnatal effects: Possible long-term neurodevelopmental impacts reported in animal studies. |
| Fetal Monitoring | Monitor blood pressure, liver function, glucose tolerance; fetal ultrasound for growth and anatomy if exposed during second/third trimester. Assess for signs of thromboembolism. |
| Fertility Effects | Returns to baseline after discontinuation with no permanent effect on fertility. Temporary delay in return to ovulation possible. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women >35 years who smoke should not use this product.
| Common Effects | Nausea, Vomiting, Headache, Breast tenderness, Breakthrough bleeding, Spotting, Weight changes, Mood changes, Acne |
| Serious Effects | Venous thromboembolism (VTE), Arterial thromboembolism (e.g., stroke, myocardial infarction), Hepatic adenoma or hepatocellular carcinoma, Hypertension, Gallbladder disease, Thrombotic thrombocytopenic purpura (TTP), Hemolytic uremic syndrome (HUS) |
PregnancyBreastfeedingThromboembolic disordersEstrogen-dependent neoplasiaAbnormal genital bleedingLiver diseaseKnown or suspected pregnancy
| Precautions | Increased risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI), Hepatic neoplasia risk, Liver disease (e.g., jaundice, hepatitis), Elevated blood pressure, Gallbladder disease, Carbohydrate/lipid metabolic effects, Ocular lesions (e.g., retinal thrombosis), Menstrual irregularities/breakthrough bleeding, Use in pregnancy (should be ruled out before initiation), Depression |
| Food/Dietary | No specific food interactions are reported. However, grapefruit juice may increase ethinyl estradiol levels but interaction is considered weak; avoid excessive grapefruit juice consumption. Ferrous fumarate may reduce absorption of tetracycline antibiotics if taken together; space doses by at least 2 hours. No dietary restrictions are required. |
| Clinical Pearls | Junel Fe 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 mcg and norethindrone 1.5 mg, with ferrous fumarate as placebo. Consider starting on first day of menses or first Sunday after onset. Missed pills increase pregnancy risk; if missing one pill, take as soon as remembered. For missed two pills in week 1 or 2, take two pills daily for two days and use backup contraception. If missed in week 3, consider finishing current pack and skipping placebo, or starting new pack the next day. Drug interactions include rifampin, certain anticonvulsants, and St. John's wort, which may reduce efficacy. Monitor for DVT, PE, stroke, and MI, especially in smokers over 35, hypertensive, diabetic, or obese patients. |
| Patient Advice | Take one tablet daily at the same time; do not skip days. · If you miss a pill, refer to the package instructions or ask your healthcare provider. · Use backup contraception (e.g., condoms) if you miss pills or start late. · Common side effects include nausea, breast tenderness, and breakthrough bleeding. · Seek emergency care for severe abdominal pain, chest pain, leg swelling, or vision changes. · Smoking increases risk of serious cardiovascular effects; avoid smoking, especially if over 35. · Iron supplements are included; ferrous fumarate in placebo tablets is not effective for contraception. |
Loading safety data…